期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Extracellular signal-regulated kinase, substance P and neurokinin-1 are involved in the analgesic mechanism of herb-partitioned moxibustion 被引量:7
1
作者 Zhi-yuan Li Yan-ting Yang +8 位作者 Jue Hong Dan Zhang Xiao-fei Huang Li-jie Wu Huan-gan Wu Zheng Shi Jie Liu Yi Zhu Xiao-peng Ma 《Neural Regeneration Research》 SCIE CAS CSCD 2017年第9期1472-1478,共7页
Herb-partitioned moxibustion can effectively mitigate visceral pain, a major symptom in inflammatory bowel disease, but the analgesic lnechanism is still unclear. Moreover, extracellular signal-regulated kinase, subst... Herb-partitioned moxibustion can effectively mitigate visceral pain, a major symptom in inflammatory bowel disease, but the analgesic lnechanism is still unclear. Moreover, extracellular signal-regulated kinase, substance P, and neurokinin-1 are involved in formation of central hyperalgesia. Thus, we postulated that the analgesic effect of herb-partitioned moxibustion may be associated with these factors. Accordingly, in this study, we established an inflammatory bowel disease visceral pain model in rat by enema with a mixed solution of 5% trinitrobenzenesulfonic acid and 50% ethanol. Bilateral Tianshu (ST25) and Qihai (CV6) points were selected for herb-partitioned moxi- bustion. Our results showed that herb-partitioned moxibustion improved visceral pain and down-regulated extracellular signal-regulated kinase, substance P, and neurokinin-1 protein and mRNA expression in dorsal root ganglia. These results indicate that down-regulation of extracellular signal-regulated kinase, substance E and neurokinin-1 protein and mRNA may be a central mechanism for the analgesic effect of herb-partitioned moxibustion. 展开更多
关键词 nerve regeneration inflammatory bowel disease visceral pain herb-partitioned moxibustion analgesic effect Tianshu (ST25) Qihai (CV6) dorsal root ganglion extracellular signal-regulated kinase substance P neurokinin-i neural regeneration
下载PDF
止吐新药——神经激肽1受体拮抗药福沙匹坦 被引量:4
2
作者 何光照 王为欢 贺国芳 《中国药师》 CAS 2016年第4期752-755,共4页
神经激肽1受体拮抗药(NK1RA)福沙匹坦是一种新型止吐药,其二甲葡胺盐于2008年1月经FDA批准上市,在我国正处于新药申报阶段。福沙匹坦二甲葡胺为前体药,经静脉给药后在体内快速转变为活性形式阿瑞匹坦,在临床上主要用于治疗化疗相关性恶... 神经激肽1受体拮抗药(NK1RA)福沙匹坦是一种新型止吐药,其二甲葡胺盐于2008年1月经FDA批准上市,在我国正处于新药申报阶段。福沙匹坦二甲葡胺为前体药,经静脉给药后在体内快速转变为活性形式阿瑞匹坦,在临床上主要用于治疗化疗相关性恶心呕吐(CINV),尤其是迟发性呕吐。福沙匹坦独特的静脉用药制剂克服了阿瑞匹坦只能口服的限制,生物利用度不受患者呕吐的影响,也可用于口腔黏膜炎不宜口服用药的患者。本文介绍福沙匹坦的药理学、药动学特征,以及用于CINV的临床研究进展,以期为医疗人员了解该药提供参考。 展开更多
关键词 福沙匹坦 阿瑞匹坦 神经激肽1受体拮抗药 化疗相关性恶心呕吐
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部